Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 5

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 5
---
 represented by
Depositary Shares) in excess of 4.99% of the then-outstanding Ordinary Shares (including Ordinary Shares represented by Depositary Shares)
following such purchase or acquisition by the Purchaser (the “Beneficial Ownership Limitation”), provided, however, the Purchaser
may increase the Beneficial Ownership Limitation up to 9.99% at its sole discretion upon sixty-one days’ prior written notice to
the Company. For the avoidance of doubt, the Beneficial Ownership Limitation in no event will exceed 9.99% of the number of Ordinary Shares
(including Ordinary Shares represented by Depositary Shares) outstanding immediately after giving effect to the issuance of shares of
Ordinary Shares (including Ordinary Shares represented by Depositary Shares) pursuant to the Purchase Agreement.

The
net proceeds under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares to
the Purchaser. The Company expects that any proceeds received by the Company from such sales to the Purchaser will be used to fund its
development program, for working capital and other general corporate purposes.

The
Company has the right to terminate the Purchase Agreement at any time, upon one business day’s notice, at no cost or penalty. During
any “suspension event” under the Purchase Agreement, the Purchaser does not have the right to terminate the Purchase Agreement;
however, the Company may not initiate any regular or other purchase of shares by the Purchaser, until such event of default is cured.
In addition, in the event of bankruptcy proceedings by or against the Company, the Purchase Agreement will automatically terminate in
accordance with the terms of the Purchase Agreement.

Registration Rights Agreement

Concurrent
with the execution of the Purchase Agreement, the Company entered into a registration rights agreement with the Purchaser (the “Registration
Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company agreed to file a registration statement on Form F-1
with the SEC covering the resale of the Securities, on or before the 45th calendar day following the date of the Registration Rights Agreement
and to use its commercially reasonable efforts to cause such registration statement to be declared effective by the SEC at the earliest
practicable date, subject to limited exceptions described therein. The registration rights granted under the Registration Rights Agreement
are subject to certain conditions and limitations and are subject to customary indemnification and contribution provisions.

The
foregoing descriptions of the Purchase Agreement and the Registration Rights Agreement do not purport to be complete